Cell Transplantation最新文献

{"title":"Long-term survival of autologous peripheral nerve fascicles transplanted into the substantia nigra of participants with Parkinson disease: Preliminary observations.","authors":"Ares Marlonsson, Jorge E Quintero, Henric Ek-Olofsson, Ann-Charlotte Granholm, Craig G van Horne, Greg A Gerhardt","doi":"10.1177/09636897261495817","DOIUrl":"https://doi.org/10.1177/09636897261495817","url":null,"abstract":"<p><p>Cell transplantation therapies for Parkinson disease (PD) require confirmation that grafted tissue withstands the degenerative environment of the diseased brain. Autologous peripheral nerve tissue (PNT) grafts transplanted into the substantia nigra (SN) have been investigated in an ongoing clinical program, but characterization of graft survival after extended periods in the human CNS has been limited. We present histological and immunohistochemical analysis of PNT grafts in postmortem tissue from two participants who lived 7 years 11 months and 9 years 2 months following transplantation. Grafts persisted as structurally organized tissue with preserved fascicular architecture, compartmentalized boundaries defined by convergent GFAP-negative and COL1A1-positive demarcation, and cellular density comparable to naïve sural nerve. Immune cell presence within grafts was limited (4-7%) and concentrated at graft-host interfaces. Vascular networks including CD31-positive capillaries and SMA-positive arterioles were identified within grafts. Transplanted tissue maintained PNS identity with Schwann cell markers p75NTR, S100B, and MPZ detected within grafts, contrasting MBP expression in surrounding parenchyma. TH-positive processes within grafts, spatially associated with MPZ immunoreactivity, supported interactions between grafted Schwann cells and catecholaminergic processes consistent with dopaminergic origin. These findings provide histological evidence that autologous PNT grafts persist as organized, cellularly viable, transplanted tissue with maintained PNS identity after extended survival in the parkinsonian SN.</p>","PeriodicalId":9721,"journal":{"name":"Cell Transplantation","volume":"35 ","pages":"9636897261495817"},"PeriodicalIF":3.7,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149164597","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Personalized allogeneic hematopoietic stem cell transplantation in myelodysplastic syndromes: Integrating molecular risk, donor selection, and post-transplant strategies.","authors":"Yu Wang, Xumeng Zhao, Mi Zhou, Yi Xiao","doi":"10.1177/09636897261499610","DOIUrl":"https://doi.org/10.1177/09636897261499610","url":null,"abstract":"<p><p>Allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains the only treatment with curative potential for myelodysplastic syndromes (MDS). This review synthesizes MDS-specific evidence on transplant indication and timing, conditioning, donor choice, molecular predictors, and post-transplant surveillance. Prospective biologic-assignment studies support a survival benefit in fit older adults with higher-risk MDS. The Molecular International Prognostic Scoring System (IPSS-M), transplant-specific cytogenetic and mutational factors, comorbidity, and transfusion burden refine selection beyond the Revised International Prognostic Scoring System (IPSS-R). Alternative donors expand access, including haploidentical transplantation with post-transplant cyclophosphamide. Conditioning intensity should reflect both disease risk and patient fitness, with regimen-level scoring emerging for cord blood transplantation. Although non-relapse mortality has decreased over time, relapse remains the major unresolved cause of failure. MDS-specific measurable residual disease, graft-versus-host disease, cytomegalovirus assessment, and risk-adapted post-transplant interventions provide a practical framework for individualized care.</p>","PeriodicalId":9721,"journal":{"name":"Cell Transplantation","volume":"35 ","pages":"9636897261499610"},"PeriodicalIF":3.7,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149214981","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advances in stem cell-derived beta-cell therapy: A new frontier in type 1 diabetes treatment.","authors":"Krishnaa Shivkant Upadhye, Paritosh Tayade","doi":"10.1177/09636897261417623","DOIUrl":"10.1177/09636897261417623","url":null,"abstract":"<p><p>Type 1 diabetes (T1D) is a chronic autoimmune disease characterized by the destruction of pancreatic beta cells (β-cell), leading to lifelong dependence on exogenous insulin. Despite advances in insulin delivery systems and glucose monitoring, achieving tight glycemic control remains a challenge for many patients. In recent years, stem cell-derived β-cell therapy has emerged as a promising strategy for restoring endogenous insulin production. This review explores the progress in differentiating human pluripotent stem cells, such as embryonic stem cells and induced pluripotent stem cells (iPSCs), into functional insulin-secreting β-like cells. We highlight recent breakthroughs in improving cell maturity, graft survival, and immune protection. Delivery approaches, encapsulation technologies, and transplantation strategies are discussed alongside an overview of ongoing clinical trials. The review also addresses current limitations, including immune rejection, cell dedifferentiation, and safety concerns. Finally, we examine future directions, such as genome editing, personalized cell therapy, and the integration of artificial intelligence in monitoring and optimizing treatment. Stem cell-derived β-cell therapy holds transformative potential as a curative approach for T1D, but further research is essential to overcome remaining barriers to its widespread clinical application.</p>","PeriodicalId":9721,"journal":{"name":"Cell Transplantation","volume":"35 ","pages":"9636897261417623"},"PeriodicalIF":3.7,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12905087/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146178081","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-term complete remission and minimal side effects after CD19/CD22 CAR-T cell cocktail therapy in a living donor with DLBCL: A rare case report.","authors":"Qi Zhang, Jiaying Wu, Fankai Meng, Yang Cao, Xiaojian Zhu, Yi Xiao","doi":"10.1177/09636897261446738","DOIUrl":"10.1177/09636897261446738","url":null,"abstract":"<p><p>Chimeric antigen receptor T-cell (CAR-T) therapy is a breakthrough in cancer treatment that can induce durable remission in patients with hematological malignancies who have failed prior therapies. As the use of CAR-T cell therapy increases, treatment-related renal complications deserves careful attention, particularly in patients with a solitary kidney, in whom renal complications may further increase clinical risk. Here, we report the case of a living kidney donor who was diagnosed with diffuse large B-cell lymphoma (DLBCL). After CAR-T cell therapy, the patient developed only mild cytokine release syndrome (CRS), without signs of acute kidney injury or renal impairment, and subsequently achieved a favorable metabolic response approaching complete remission.</p>","PeriodicalId":9721,"journal":{"name":"Cell Transplantation","volume":"35 ","pages":"9636897261446738"},"PeriodicalIF":3.7,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13230660/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148148654","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Autologous chemically induced liver progenitor cell transplantation ameliorates steatosis and fibrosis in a preclinical miniature pig model of metabolic dysfunction-associated fatty liver disease: A pilot study.","authors":"Takanobu Hara, Yasuhiro Maruya, Daisuke Miyamoto, Masayuki Fukumoto, Hajime Imamura, Hajime Matsushima, Akihiko Soyama, Tomohiko Adachi, Takahiro Ochiya, Susumu Eguchi","doi":"10.1177/09636897261446732","DOIUrl":"10.1177/09636897261446732","url":null,"abstract":"<p><p>Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common chronic liver disorder and can progress to steatohepatitis and fibrosis; although approved pharmacotherapies for metabolic dysfunction-associated steatohepatitis (MASH) with fibrosis remain limited. Autologous chemically induced liver progenitor (CLiP) cells, generated from mature hepatocytes without genetic modification, have shown therapeutic promise in rodents, but their efficacy has not been tested in large animals. Six female Clawn miniature pigs (15-42 kg) were fed a high-fat, high-cholesterol diet to induce MASLD with biopsy-proven fibrosis (Brunt stage ≥1). Animals were assigned to CLiP transplantation (<i>n</i> = 3) or saline control (<i>n</i> = 3). Autologous CLiPs (5 × 10⁷) were generated from laparoscopically resected liver wedges, expanded <i>ex vivo</i>, and infused intraportally. Safety was assessed by monitoring, liver function tests, and lipid profiles. Efficacy was evaluated 1 month later by blinded histology and immunohistochemistry. CLiP transplantation was feasible and well tolerated. Serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) showed minimal changes in both groups, but total cholesterol and triglycerides decreased in treated pigs and increased in controls. Histologically, two of three CLiP-treated livers regressed from Brunt stage 1 to 0, with resolution of steatosis and reduced stellate cell activation, whereas controls showed no regression. These findings support CLiP therapy as a regenerative option for MASLD.</p>","PeriodicalId":9721,"journal":{"name":"Cell Transplantation","volume":"35 ","pages":"9636897261446732"},"PeriodicalIF":3.7,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13237254/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148148624","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Preclinical safety assessment and immunological evaluation of xenogeneic mammary cells of porcine origin, utilized as an intralesional immunotherapeutic agent.","authors":"Liang-Chih Liu, Chih-Rong Shyr, Ting-Yu Lin, Ching-Feng Wu, Chen-Kai Shih, Wen-Lung Ma, Chi-Yu Yang, Chi-Ping Huang","doi":"10.1177/09636897251406337","DOIUrl":"10.1177/09636897251406337","url":null,"abstract":"<p><p>Xenogeneic cells isolated from safe animal tissues and expanded <i>ex vivo</i> hold potential as immunotherapeutic agents capable of stimulating the body's immune system to treat cancers. This study aimed to evaluate the <i>in vivo</i> safety and immunological effects of xenogeneic mammary cells of porcine origin (XMC), ensuring that their local administration is a safe medical intervention for breast cancer treatment. The safety of local XMC treatment was assessed by injecting varying doses of these cells into the abdominal mammary fat-pad tissues as prime and booster shots. Over a 28-day observation period, the tested dose range showed no significant changes in body weight or organ weight, and histopathological analysis revealed no pathological alterations in liver or kidney tissues. No abnormal findings were observed in hematology and serum biochemistry parameters. However, a dose-dependent periductal inflammation and lymphoid tissue infiltration were observed at the injection site. To further assess immune responses to xenogeneic cells, we evaluated their ability to stimulate immune cell proliferation and cytokine secretion in co-cultures with mouse splenocytes and human leukemia cell lines. Cell proliferation was measured by flow cytometry, and cytokine was analyzed using the ELISA method. Co-cultures of mouse splenocytes, KG-1, or Jurkat cells with XMCs elicited a proliferative response and increased secretion of cytokines, including interleukin-2 and interferon gamma, which are involved in immune rejection and antitumor activity. Physical interactions between immune cells and xenogeneic cells have also been demonstrated. The mouse safety study and cell-based bioassay results indicate that XMCs were safe within the tested dose range in this preclinical <i>in vivo</i> assessment, and their immune-stimulatory effects were clearly measurable.</p>","PeriodicalId":9721,"journal":{"name":"Cell Transplantation","volume":"35 ","pages":"9636897251406337"},"PeriodicalIF":3.7,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12979918/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147430961","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Glial cells in dementia: From cellular dysfunction to therapeutic frontiers.","authors":"Hassan Jubair","doi":"10.1177/09636897251414216","DOIUrl":"10.1177/09636897251414216","url":null,"abstract":"<p><p>Neurodegenerative dementias, including Alzheimer's disease and vascular dementia, have long been viewed through a neuron-centric lens. However, growing evidence highlights the indispensable and multifaceted roles of glial cells, astrocytes, microglia, and oligodendrocytes in both the onset and progression of these disorders. While prior reviews have cataloged glial dysfunction in isolation, this review offers a novel, integrative framework that maps the interconnected roles of glial subtypes across molecular, cellular, and circuit-level pathology in dementia. We critically synthesize recent advances in single-cell RNA sequencing, spatial transcriptomics, and glial imaging to redefine glial heterogeneity and function in disease states. Special emphasis is placed on the dynamic cross talk between glial populations and the feedback loops that govern their dual roles in neuroprotection and neurodegeneration. Furthermore, we examine emerging therapeutic strategies targeting glial-specific pathways, including NF-κB, JAK/STAT, CSF1R, and TREM2 signaling, as well as remyelinating agents and stem cell-based interventions. By integrating glial biology with therapeutic innovation, this review positions glial cells not as supporting actors but as central regulators and potential gatekeepers of dementia pathogenesis and treatment.</p>","PeriodicalId":9721,"journal":{"name":"Cell Transplantation","volume":"35 ","pages":"9636897251414216"},"PeriodicalIF":3.7,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12909748/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146200301","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Vascularized composite xenotransplantation: Where we have been and where we could go?","authors":"Tobias Niederegger, Thomas Schaschinger, Gabriel Hundeshagen, Samuel Knoedler, Jule C Brandt, Jan O Voss, Max Heiland, Curtis L Cetrulo, Alexandre G Lellouch, Leonard Knoedler","doi":"10.1177/09636897261431041","DOIUrl":"10.1177/09636897261431041","url":null,"abstract":"<p><p>Vascularized composite allotransplantation (VCA) enables functional and aesthetic reconstruction after complex tissue loss but remains limited by donor scarcity and immunosuppression. Xenotransplantation, using tissues from other species, offers a potential solution. While progress in solid organ xenografts has accelerated, vascularized composite xenotransplantation (VCX) remains largely experimental. This study presents the first systematic review of VCX, tracing its development over the past century and preclinical efforts to overcome immunologic and technical barriers. A systematic review following Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 guidelines searched PubMed, EMBASE, Cochrane, Web of Science, and Google Scholar for English-language VCX studies. Methodological quality was assessed using the Newcastle-Ottawa Scale, SYRCLE Risk of Bias tool, and Oxford Levels of Evidence. Of 257 records, six preclinical studies (1885-2023) met inclusion criteria. Donor species included pigs, rabbits, dogs, and humans; recipients were rodents or nonhuman primates. Most used heterotopic grafts (e.g., limbs, groin flaps, thymosternal blocks) combining skin, muscle, bone, and nerves. Techniques included cryopreservation, microsurgical anastomosis, and genetically modified pig grafts (e.g., GalTKO.hCD46). All demonstrated short-term survival without long-term function. Despite technical feasibility, VCX remains experimental. Advances in gene editing, immune modulation, and tissue engineering are essential for clinical translation and may ultimately redefine reconstructive transplantation.</p>","PeriodicalId":9721,"journal":{"name":"Cell Transplantation","volume":"35 ","pages":"9636897261431041"},"PeriodicalIF":3.7,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13009779/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147472407","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Research landscapes and knowledge structure of cardiac xenotransplantation: A bibliometric analysis.","authors":"Shangxuan Li, Guanzheng Cui, Ziqiang Dai, Zhipeng Ren, Jiahong Wang, Xianzhi Wang, Gen Zhang, Dongsheng He, Huan Wang, Xin Li, Dianyuan Li","doi":"10.1177/09636897261431049","DOIUrl":"10.1177/09636897261431049","url":null,"abstract":"<p><p>Cardiac xenotransplantation is advancing rapidly from basic research to early clinical use, but its research landscape has not been comprehensively mapped. We conducted a bibliometric and science-mapping analysis of English-language articles and reviews in the Web of Science Core Collection (1964-2025). Using VOSviewer, CiteSpace, and Bibliometrix, we assessed publication growth, collaboration networks, citation impact, and topic trends. The field has grown steadily and has accelerated in recent years in parallel with key clinical developments. Collaboration is strongest among institutions in the United States, Europe, and East Asia, and a small number of authors and centers contribute a large share of publications. Most studies are published in specialty transplantation journals, whereas major breakthroughs often appear in general medical journals. Research topics continue to focus on rejection and complement biology, while newer work highlights gene-edited donors, biosafety, clinical trial readiness, and pig-to-human models. Overall, the field appears to be maturing toward clinical implementation, and these findings can help guide research priorities, funding decisions, and policy planning.</p>","PeriodicalId":9721,"journal":{"name":"Cell Transplantation","volume":"35 ","pages":"9636897261431049"},"PeriodicalIF":3.7,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13009822/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147484899","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pre-transplant <i>Clostridioides difficile</i> infection predicts subsequent gastrointestinal GVHD and non-relapse mortality after allogeneic hematopoietic stem cell transplantation.","authors":"Wenyi Wang, Yibo Wu, Yunbo Chen, Xiaoyu Lai, Lizhen Liu, Jimin Shi, Yanmin Zhao, Luxin Yang, Lin Li, Jian Yu, Huarui Fu, Panpan Zhu, He Huang, Yi Luo","doi":"10.1177/09636897261461629","DOIUrl":"10.1177/09636897261461629","url":null,"abstract":"<p><p>This study aimed to define the incidence of <i>Clostridioides difficile</i> infection (CDI), identify its risk factors, and evaluate its association with early post-transplant complications and overall clinical outcomes. To characterize CDI in the allogeneic hematopoietic stem cell transplantation (allo-HSCT) setting, we retrospectively analyzed a cohort of 539 recipients who experienced diarrhea in the peri-transplant period (from conditioning to discharge from laminar flow). Among these diarrheic recipients, 64 patients developed CDI, the cumulative incidence of CDI was 12.1%, with a median onset of day -1 (range, -7 to +26) relative to HSCT. In a multivariate analysis, older age was independently associated with a lower risk of CDI (HR, 0.97; P = 0.008) among diarrheic recipients. The incidence of CDI stratified by the median onset time revealed that pre-transplant CDI was an independent risk factor for grade 1-4 lower gastrointestinal acute graft-versus-host disease (lower-GI aGVHD) (HR, 2.43; P=0.024). Furthermore, pre-transplant CDI was associated with a markedly increased risk of severe fungal infection (HR,6.97; P=0.026) and 100-day non-relapse mortality (NRM) (HR, 3.13; P=0.046). In conclusion, this study highlights a critical, timing-dependent distinction in CDI-associated severe complications and mortality in allo-HSCT recipients with diarrhea.</p>","PeriodicalId":9721,"journal":{"name":"Cell Transplantation","volume":"35 ","pages":"9636897261461629"},"PeriodicalIF":3.7,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13264668/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148249290","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}